The FDA has approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) from AbbVie, an all-oral, interferon-free...
The FDA granted final approval of a New Drug Application for Kitabis Pak, from PulmoFlow, a co-packaging of generic tobramycin...
Phathom Pharmaceuticals, Inc. announced regulatory updates for its approved products, Voquezna Triple Pak and Voquezna Dual Pak, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application (NDA) for vonoprazan for the treatment of erosive esophagitis
Medtronic plc announced it has received FDA approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN)
A 200-patient Phase II pilot study has begun to examine the efficacy and safety of the Shok-Pak, from InflammaGen Therapeutics,...
AbbVie has announced new data from its ongoing Phase IIIb TOPAZ-II study evaluating Viekira Pak (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir...
AbbVie’s New Drug Application (NDA) has been accepted by the FDA for a once-daily, fixed-dose formulation of the components of...
Abbott has announced that the FDA has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes
The FDA has approved a supplemental New Drug Application (sNDA) for the use of Viekira Pak (ombitasvir, paritaprevir, and ritonavir...
In consultation with the FDA, the US prescribing information for Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and...